Renovion

Renovion is a private, clinical-stage biotech developing ARINA-1, a novel nebulized therapy targeting the vicious cycle of mucus, inflammation, and infection in chronic lung diseases. The company has generated positive Phase 2 top-line results in NCFBE and is actively enrolling a trial in lung transplant, positioning it in underserved markets with significant unmet need. Led by a seasoned team with deep respiratory expertise, Renovion's approach aims to improve mucociliary clearance and quality of life for patients with limited treatment options.

ARINA-1 is a novel, nebulized small molecule therapy with a multi-modal mechanism of action designed to break the cycle of mucus, inflammation, and infection in the lungs. It improves mucociliary clearance, reduces inflammation comparably to steroids without their side effects, and inhibits bacterial growth.

In NCFBE, competition includes off-label use of hypertonic saline, dornase alfa, and manual airway clearance techniques, but there are no approved pharmacologic mucolytics. In lung transplant, there are no approved drugs for BOS/CLAD. Larger pharmaceutical companies (e.g., AstraZeneca, GSK, Vertex) are active in respiratory diseases but have not focused on these specific muco-obstructive indications, leaving a potential niche for Renovion.